The tests are designed to detect regions in the SARS-CoV-2 genome in respiratory samples or antibodies against the virus in human serum, plasma, or blood.
Investigators are building upon an initial case study that allowed them to assess how well ctDNA captured a cancer's full genomic heterogeneity compared to tissue biopsies.
All three methods build on the use of methyltransferases to mark accessible regions of the genome, using nanopore sequencing to detect the modifications.
